The markets for generic infectious disease pharmaceuticals in sub-Saharan Africa hold considerable potential. Despite high levels of poverty and market price sensitivity, the region has a large and growing population that is increasingly able to pay for better health services and pharmaceutical products. New analysis from growth consulting company Frost & Sullivan (http://www.pharma.frost.

More: continued here

This entry was posted on Saturday, March 15th, 2008 at 12:03 am and is filed under Infectious Diseases / Bacteria / Viruses. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.